Diagnosis & Disease Information

Human lungs

Pirfenidone Inhibits MRTF Signaling With an Elusive Antifibrotic Mechanism in IPF

Although treatment of idiopathic pulmonary fibrosis (IPF) with pirfenidone significantly slows the decline in pulmonary function, the antifibrotic mechanism of the agent remains elusive. The underlying pathophysiology of IPF is complex and not well understood, with the disease likely triggered by repetitive microinjuries to the airway and alveolar epithelium. A recent study utilized transcriptomic and…

Liposome encapsulation

Targeting Pathological Collagen a Promising New Treatment Strategy in IPF

A study reports promising results from a new strategy to target pathological collagen in idiopathic pulmonary fibrosis (IPF) by delivering antifibrotic drugs via penetrating liposomes directly to injured alveoli. The study, published in the Journal of Control Release, determined that the liposomes were able to deliver pirfenidone and dexamethasone to repair and remodel the lung…

IPF

Pirfenidone Also Beneficial in Probable or Possible Idiopathic Pulmonary Fibrosis

Pirfenidone treatment leads to favorable outcomes in patients with probable or possible idiopathic pulmonary fibrosis (IPF), as it does in patients with definitive disease. These findings were reached in a European MultiPartner IPF Registry (EMPIRE) analysis published in PLoS One. Pirfenidone is widely used to treat patients with IPF. However, it is not known whether…

Study Identifies Prognostic Factors in Incidentally Diagnosed IPF Cases

Approximately one-third of patients are diagnosed with idiopathic pulmonary fibrosis (IPF) in Japan either during a routine health checkup or while undergoing an examination for another disease, while experiencing minimal or no respiratory symptoms, according to a new study published in Respiratory Medicine. In spite of being diagnosed at a relatively early stage of disease,…

IPF Phase 2b Monoclonal Antibody Study Terminated

A randomized, double-blind, placebo-controlled phase 2b study was terminated due to adverse events (AEs) and a lack of efficacy of BG00011, an anti-αvβ6 immunoglobulin G1 monoclonal antibody, as therapy for idiopathic pulmonary fibrosis (IPF), according to a study published in the American Journal of Respiratory and Critical Care Medicine. The study was carried out after…

Inhaler for spray and powder

Pirfenidone-Loaded Nanoparticles as an Alternate Treatment for IPF

Pirfenidone-loaded chitosan nanoparticles are stable after 6 months, a new study published in the Future Journal of Pharmaceutical Sciences found. The nanoparticles could be used as a better alternative to treat idiopathic pulmonary fibrosis (IPF) since they can enhance the concentration of pirfenidone in deep lung tissues with a single, lower dose. Pirfenidone has already…

cardiovascular disease

Comorbidities in IPF Linked With Poor Survival

Researchers discovered that patients with idiopathic pulmonary fibrosis (IPF) tend to have multiple comorbidities, which is associated with poorer survival, even in patients receiving antifibrotic therapy, as published in Respiratory Research. Patients with IPF often struggle with a high disease burden and experience pulmonary and extrapulmonary comorbidities. These commodities can be caused by risk factors…

pulmonary fibrosis

Coadministered Cudetaxestat Shows Potential in IPF Trial

Cudetaxestat is well tolerated and leads to no treatment-related serious adverse events when coadministered with pirfenidone or nintedanib in healthy volunteers, according to the results of a phase 1 clinical trial. There were also no drug-drug interactions with cudetaxestat plus pirfenidone or nintedanib. These results were presented at the American Thoracic Society 2022 International Conference.…

gettyimages

New Radiomics Model Predicts Response to Antifibrotic Treatment in IPF

Researchers have discovered that radiomic features can be used to predict the therapeutic response of patients with idiopathic pulmonary fibrosis (IPF) to antifibrotic agents, as published in Diagnostics. IPF causes excessive fibrotic deposition in the lung parenchyma, eventually resulting in respiratory failure. This disease carries a poor prognosis, with mortality usually occurring within 5 years…

drug research

Cudetaxestat Advances to Phase 2 Trial for IPF

The requirements for a phase 2 PoC/dose-ranging study of cudetaxestat for patients with idiopathic pulmonary fibrosis (IPF) have been outlined by the US Food and Drug Administration (FDA), according to a press release by Blade Therapeutics. Pending preclinical toxicity studies, the company will carry out the trial in the second quarter of 2022. “Taking a…

Next post in IPF News Briefs